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1. Introduction 
We began our journey researching cannabis as a medicine roughly twelve years ago and 
have been astounded time and time again at the profound effectiveness of the plant. In this 
chapter we will describe the usefulness of cannabis in pain management. In so doing we will 
be describing the whole plant medicine such as is dispensed in compassion clubs and medical 
marijuana dispensaries here in British Columbia, Canada and similarly in California and 
other parts of the world where cannabis has become legal as a medicine.  
We treat cannabis as the herbal medicine that it is. What we do; is apply high tech 
instrument analysis of the plant and scientific method to members using cannabis 
therapeutically in attempts to unravel the truth of its efficacy and safety. We have set up 
research departments, collected membership data, run literally thousands of chromatograms 
and worked closely with persons with chronic pain at local dispensaries and cannabis clubs 
here in British Columbia for many years. 
What we will describe in the chapter is primarily repeated observation of members of 
medical marijuana dispensaries who routinely use cannabis to deal with pain. Of the clubs 
we have worked with over the years most of their members are using cannabis for pain 
management. Often greater than 70% of the members surveyed will be using cannabis for 
this purpose. This holds true for medical dispensaries here in B.C. as well as for California, 
Holland and Switzerland (1). Simply put, most persons frequenting medical cannabis 
dispensaries are there for pain management. 
Many of the people we have worked with over the years have been terribly broken up, 
either in car accidents, on the job injuries, infection (Reiter’s syndrome), surgeries or cancer 
therapy, plus many other causes, that lead to 24/7 chronic pain. As if the pain isn’t bad 
enough, often cycling with the pain is mood disorder, such as depression, attention deficit 
disorder and anxiety. 
When it is difficult to put on a jacket, climb a flight of stairs or tie shoelaces, normal life is 
affected and the individual adjusts by changing their life style in attempts to relieve pain. 
These adjustments can often bring on anxiety (not being able to go out) or depression 
(relating to friends and family) since now the person’s lifestyle is not as it used to be…now it 
is ruled by pain. 
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Fig. 1. Acknowledgement to: http://naturalbodyofflorida.webs.com/pain-
map_alphachimp_com.jpg for this explicit graphic. 
For those dealing with pain it often becomes a fulltime job: monitoring, medicating, resting, 
exercising, eating, going to bed, take on new meaning when one is in pain. Constantly 
seeking relief from “the banging drum,” as quoted by Dr. Mel Pohl (2), being the top 
priority for those who suffer. Relief from pain leads to a new quality of life that, in turn, 
breaks the cycle of chronic pain syndrome.  
Cannabis allows new quality of life for many suffering from chronic pain. 
Having access to the member’s data allows determination of; how much cannabis they’re 
using daily, in what form (smoke able or edible), what strain is preferred, their ailment, etc. 
This accumulated data is used to take perspective on the cannabis use of the membership of 
the individual clubs and to track various individuals included in studies.  
We have spent five years with our laboratory serving the quality control and 
standardization needs of one such dispensary, and the past two doing similar duties and 
research at a second. In all of this time we maintain close association with the members who 
use cannabis therapeutically for pain, tracking their symptoms with questionnaires, 
interviews, pain charts, emails, etc.  
We have found a psychology that prevails at these dispensaries; they’re friendly, non-
violent, people whom all seem to be willing to take part in the scientific research that is 
being carried out. No shortage of volunteers. And many have sustained and continue to 
deal with disabling injuries that have dramatically affected their lives and families. 
Currently we have joined with five medical dispensaries in our local area and are initiating 
Randomized Controlled Trials (RCT) with roughly one hundred volunteer subjects together 
taking part in the placebo controlled trial. Our focus will be arthritic pain and we look 
forward to publication before the end of 2012.  
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2. The legalities 
Cannabis has been legal as a medicine, in Canada, since 2001, when a precedent setting 
court case ruled that Canadians had a constitutional right to the plant for medical purposes 
(3). The Medical Marijuana Access Regulations (MMAR) was established in that year 
allowing qualified individual’s licenses to possess and produce their own cannabis for 
medical reasons.  
Only persons who were terminally ill, with severe spinal cord injury, arthritis or multiple 
sclerosis and unresponsive to routine medical treatment were originally allowed a cannabis 
license. Often these people were too ill to grow their own, so designated growers were also 
assigned licenses to specific qualified persons for growing cannabis. An alternative to 
obtaining an MMAR license was to have a medical doctor fax a letter of acknowledgement 
of an individuals cannabis use to a local dispensary, releasing the dispensaries from some of 
the quasi-legal burden of distributing cannabis to members. 
Overall the MMAR program has demonstrated itself to be lacking in meeting the needs of 
it’s licensees, with long wait times for initial and renewal licensing and poor supply of 
government marihuana for those unable to grow for themselves or without a designate. 
Because of these shortcomings and yet another court case the program is about to be 
revamped once again to tighter government and industry control. 
Nevertheless, most persons in Canada, at this time, with a legitimate complaint of chronic 
pain and a tenacious attitude can access medical marijuana.  And most would do this with 
their own licensed grows or through dispensaries.  
3. The endocannabinoids 
As it turns out the receptor that binds THC is one of the most abundant binding sites in the 
human brain. Expressed at high levels in the hippocampus, cortex, cerebellum, and basal 
ganglia (4–6), the receptor, is virtually everywhere. An unusual receptor type in that binding 
occurs at the pre-synapse (upstream) side of the cleft, a type of receptor mechanism, called 
retrograde signaling. Different, in that depolarization at the post-synapse opens voltage-
dependent Ca2+ channels, that in turn, activates enzymes that produce endocannabinoids 
from lipid precursors, in the cell membrane. See Figure 2, courtesy of Dr. Roger Nicoll (7), 
that illustrates retrograde signaling.  
In the Hippocampus, for example, these highly fat-soluble compounds migrate back across 
the synapse to the pre-synaptic CB1 receptors where binding slows release of the inhibitory 
neurotransmitter, GABA. G-protein activation liberates Gbg (a receptor subunit), which then 
directly inhibits presynaptic Ca2+ influx, thus preventing release of neurotransmitter vesicles 
from the presynapse.  
Until just a few years ago this type of receptor signaling was unheard of but today 
characterizes the endocannabinoid mechanism of neuromodulation, protection and 
plasticity.  
In their review, Hohmann and Suplita state that: “Cannabinoid receptors are localized in 
neuroanatomical regions subserving transmission and modulation of pain signals, such as 
the periaqueductal gray (PAG), the rostral ventromedial medulla (RVM), ( 8,9) and the 
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dorsal horn of the spinal cord.(9) These findings suggest that endocannabinoids play a key 
role in central nervous system modulation of pain signaling. 
 
Fig. 2. Retrograde signaling by endocannabionids. Postsynaptic depolarization opens voltage-
dependent Ca2+ channels; postynaptic Ca2+ then activates enzymes that synthesize 
endocannabinoids from lipid precursors. Activation of postsynaptic mGluRs can also generate 
endocannabinoids possibly by activation of phospholipase C, generating diacylglycerol, , 
which is then cleaved by diacylglycerol lipase to yield 2-arachidonylglycerol. 
Endocannabinoids then leave the postsynaptic cell and activate presynaptic CB1 receptors.  
G-protein activation liberates Gβγ, which then directly inhibits presynaptic Ca2+ influx. This 
decreases the probability of release of a vesicle of neurotransmitter. 
Significantly, immunocytochemical studies have demonstrated FAAH expression in the 
ventral posterior lateral nucleus of the thalamus,(10-12) which is the termination zone of the 
spinothalamic tract. This pathway is the major source of ascending nociceptive information 
to the brain. Furthermore, FAAH has been identified in Lissauer’s tract and in neurons of 
the superficial spinal cord dorsal horn (i.e., in close proximity to the termination zone of 
nociceptive primary afferents). These observations confirm that a mechanism for 
endocannabinoid deactivation is present in regions of the central nervous system implicated 
in nociceptive processing and further support the notion that endocannabinoids play a role 
in pain modulation.”  
Since the endocannabinoid system includes the G-protein receptors and subunits, the 
ligands that bind the receptors and the enzymes that make or breakdown the ligands, 
attention has been paid to all these components in relation to pain.  
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Mice bred with no CB1 receptors tend to hide in corners, die young and show high 
incidence of cataplexy and hypoalgesia, or decreased sensitivity to painful stimuli. It was 
experiments such as these that indicated the role of the endocannabinoid system in the 
modulation of nociception and pain. And, indeed, the tremendous abundance of the 
neuromodulatory CB1 receptor in the human central nervous suggests a regulatory role of 
neurotransmission, far greater than that commanded by the opiate system. 
Research carried out between 2005 and 2010 indicates that synthetic cannabinoids and 
inhaled cannabis are effective treatments for a range of neuropathic disorders.[13]  Smoked 
cannabis has been found to provide relief from HIV-associated sensory neuropathy.[14] This 
form of cannabis was also found to relieve neuropathy associated with CRPS type I, spinal 
cord injury, peripheral neuropathy, and nerve injury.[15] 
3.1 CB2 receptor 
Changes in endocannabinoid levels and/or CB2 receptor expressions have been reported in 
almost all diseases affecting humans [16].  CB2 receptors are found mostly in peripheral 
immune tissues such as the spleen, tonsils and thymus glands where they’re primarily 
localized on immune cells such as monocytes, macrophages, B-cells, and T-cells.[17-20] 
Reducing intracellular levels of cyclic adenosine monophosphate (cAMP), leads to a series of 
down-regulatory events ultimately resulting in lowered immunity. Other types of 
cannabinoid receptors (CB3) are proposed and will undoubtedly more will emerge as 
research continues. 
Several putative endocannabinoids have been isolated in the brain, including anandamide, 
2-AG, noladin ether, virodhamine, and N-arachidonoyldopamine (NADA), the latter 
neurotransmitter decidedly involved with the vanilloid receptor and nociception. 
4. Dosage 
The first step in pain relief is accessing cannabis, once obtained…relief begins. 
4.1 Oral vs. smoking  
Often the initial use of cannabis for a person in chronic pain is the blessing they have been 
waiting for. Normally smoked the first time, the instant relief and general well being 
brought about from cannabis are greatly appreciated.  But with smoking relief is short, 
roughly an hour or two before another dose is needed. With smoking the member of a 
dispensary or compassion club will cycle through their day with relief one hour, but not the 
next, for those with severe chronic pain, eating cannabis becomes a better solution. With oral 
ingestion the effects are often stronger and felt more “in the body than the mind” and pain 
relief is maintained for four to six hours in a plateau-like fashion rather the cyclical.  
Indeed, oral ingestion of cannabis is most often indicated for those with chronic pain. But 
one cannot just pick a bud off the plant and eat it, since raw cannabis does not contain 
activated cannabinoids that bind a receptor. In nature the cannabinoids, such as 
Tetrahydrocannabinol (THC) and Cannabidiol (CBD) are present as acids with carboxyl 
groups at the 3’ or 5’ position on the aromatic ring of the molecule, (by the terpene 
numbering system) . With the carboxyl group in place the cannabinoid does not interact 
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with the receptor; once decarboxylated, normally through heat, the carboxyl group is lost 
and THC, for example, can now bind. (see section 4.3 on smoking) 
 
CBD 
 
THC 
 
CBN 
 
THC-acid 
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Note that both CBD and CBN also have carboxyl groups as does THC-acid and most other 
cannabinoids at room temperature. 
4.2 Decarboxylation 
Decarboxylation of the major cannabinoids, tetrahydocannbinolic acid (THC-A), 
cannabidiolic acid (CBD-A) and cannabinolic acid (CBN-A), is important to understand 
particularly with oral administration of cannabis. With smoking de-carboxylation occurs by 
default with the high heat delivered through burning. With oral preparations the 
cannabinoids must be decarboxylated to produce an efficacious medicine. Most commonly 
baking the cannabis into a Brownie not only allows decarboxylation of the primary 
cannabinoids but also supplies a fatty medium, aiding in absorption of the medicine. 
Since decarboxylation requires heating a particular strain of cannabis for a specified time at 
a specific temperature to achieve optimal release of the carboxyl group, often oral 
preparations of cannabis have incomplete decarboxylation, yielding only a percentage of the 
tetrahydorcannabinolic acid (for example) as THC and thus not allowing maximum 
utilization of the active compound. 
Upon realizing the multitude of inefficient decarboxylation methods employed by many 
dispensary members preparing their own oral cannabis preparations, our research group set 
about standardizing cannabis into capsules, with known concentrations of the major actives 
(THC, CBD and CBN), for research purposes.  
We also subjected the standardized oral capsules to routine quality control procedures such 
as screening for heavy metals, pesticides and pathogenic bacteria, yeasts and molds. It is 
with these standardized capsules that most of our research into the efficacy and safety of 
cannabis as a medicine as been studied. 
4.3 Standardization 
By standardizing cannabis into orally administered capsules that we are able to better 
determine dosage and efficacy and members were able to develop regimens for treating 
pain. The standardization process involves testing by High Pressure Liquid 
Chromatography (HPLC) the raw material prior to heating to determine the amounts of the 
various acids; currently in the heating step we are mostly concerned about the concentration 
of CBD-A in the raw material, since we consider CBD an extremely important medicinal 
cannabinoid and indeed it is the last of the three, to decarboxylate with heat.  
To clarify, decarboxylation of THC-A occurs at a lower temperature than for CBD-A and 
since it is our quest to optimize the CBD concentration in a standardized prep, we must heat 
for long enough at a high enough temperature to fully decarboxylate the CBD-A. Once the 
heating step is finished the cannabis is re-ground to a fine powder and tested again by 
HPLC and encapsulated. 
In each capsule the concentration of THC, CBD and CBN, is known and of course the ratios 
of these individual cannabinoids will change depending on the strain of cannabis used 
(strain specificity, discussed below), therefore there is no generic time or temperature that 
will optimally decarboxylate every cannabis strain …they’re all different. An educated 
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guess for most strains available here in BC and in California would be 160oC (325 oF) for 45 
to 60 minutes in a sealed environment. However it is only by pre-analysis of the raw 
material, and experimentation, that we are able to set a time and temperature for optimal 
decarboxylation of a specific strain. 
The ratios of the three most abundant cannabinoids (excluding CBG), is a good indicator of 
the observed effects in an individual. For example, a ratio of roughly 1:10 CBD:THC proves 
useful for pain relief with sedation. Whereas increasing the CBN concentration relative to 
THC will bring about less pain relief and a more stimulatory effect. Point being, that the 
ratios of the individual cannabinoids one to t’other are an excellent indicator of efficacy for a 
given strain. 
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Fig. 3. HPLC (Cannabinoid) profile of a high Cannabidiol (CBD) Strain. Note the 
undecarboxylated THC-A and CBD-A, before heating. 
In terms of dosing an individual there are some important considerations. The first being the 
individual’s genealogy. It is our experience with roughly four thousand people over five 
years is that body weight is irrelevant to the effects experienced by a person using cannabis. 
Much more important is the individuals heritage or genetic background. Time and time 
again in working with persons using cannabis therapeutically it is the British Celtic (Irish, 
Scottish, Welsh) races that require more cannabis to relieve pain symptoms. Often three to 
five times more than middle Europeans, Asians or Africans, the latter, often not following 
theory as well as the former two. 
Nevertheless, it is a common observation amongst cannabis users that different races have 
different tolerances with the Celts being the most tolerant. This phenomenon is important to 
recognize in sparing many from overdose, particularly with oral preparations and persons 
with lowered tolerance to cannabis. 
Our first question in counseling an individual on cannabis use (particularly with oral 
administration) is what is their genealogy?  Celts will frequently start with 50 to 100 mg of 
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THC without experiencing any of the effects of overdose, whereas Europeans will start with 
20 to 40 mg of THC. We have recently reported two case studies (21,22) where the members 
being studied were both of Celtic origin, both dealing with pain issues and each required up 
to 500mg of THC as cannabis per day, to relieve their symptoms. 
Now how does one determine THC concentrations in cannabis buds that are to be smoked 
or even prepped into an oral dose? We will present averages taken here in British Columbia 
that correlate with other areas of the world were cannabis is being used under medical 
license. Averages of BC cannabis that was provided to the members of one BC Compassion 
club is indicative of the concentrations of three cannabinoids found in most commercial 
cannabis available here and elsewhere. 
 
THC + THC-A (total THC)  172 ( + 26) mg/gram  
CBD + CBD-A (total CBD)  3.1 ( + 0.5) mg/gram 
CBN + CBN-A (total CBN)  2.7 ( + 0.5) mg/gram 
n = 30  
Table 1. 
Review of the literature on smoked cannabis provides an average ingestion of THC 
consumed when smoking. A good rule of thumb is that 20% of the available THC is ingested 
during smoking; the other 80% is lost to atmosphere or pyrolysis. Therefore, of the average 
170-mg/gram of THC available, the patient would ingest roughly 34 mg from 1 gram of 
smoked cannabis, but since most cannabis cigarettes are normally in the 0.5-gram range, this 
would be approximately 17 mg per dose. 
One will note that the concentration of total THC is far greater than CBD or CBN, since 
breeding, lighting and fertilizer regimens have all been designed to increase THC levels in 
commercial cannabis. We feel that this is unfortunate considering the growing evidence of 
the medical benefits of CBD. It is extremely rare to find strains that have anything above 
these averages for CBD or CBN. 
Incidentally, dividing the mg/gram value by 10 provides the percent value. 
And, since decarboxylation is a one to one conversion of the acid to the alcohol moiety, with 
complete loss of the carboxyl group it is possible to administer virtually 100% of the 
available THC, CBD and CBN, in an oral preparation. 
For persons suffering from chronic pain, oral administration of cannabis is greatly preferred 
over smoking. By oral ingestion, dosing is normally every four to six hours, with the 
average in the range of 50 to 100 mg of THC, depending on genealogy, cannabis experience 
and term of use.  
4.4 Overdose 
An overdose on THC can be a terribly frightening experience. Feelings of fear, paranoia, 
confusion and vivid death thoughts can occur to a person with low tolerance and unfamiliar 
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with cannabis, who has overdosed on THC. Having done so, it is rare that an individual will 
want to repeat the event. 
Therefore, overdose is to be avoided since a member may miss out on significant pain relief 
from correct dosing, because of fear of another overdose. This is one of the important 
aspects of standardized capsules, such that a member can start small and work up, to where 
relief is found. Important to people with chronic pain, is that low doses won’t work, high 
doses can sometimes make the pain worse and medium doses are best. A medium dose 
being 50 mg for most, and 150 mg for a Scot. Sorry folks, the phenomenon of Celtic tolerance 
repeats itself too often to be ignored. 
The good thing about overdose is that no one dies. There are no recorded deaths resulting 
from cannabis use (23). One estimate of THC's LD50 for humans indicates that about 1,500 
pounds (680 kg) of cannabis would have to be smoked within 14 minutes.[24], to achieve 
toxic levels of THC. Cannabis can be considered an anti-toxin with constituents that offer 
neuroprotection, anti-oxidant activity and reduced stress. 
Robert Kampia, Founder and Executive Director of the Marijuana Policy Project. House 
Subcommittee on Criminal Justice, Drug Policy, and Human Resources. Apr. 1, 2004:  Stated 
that: “Regarding the claim that marijuana is too dangerous to be a medicine, it is interesting 
to note that there has never been a death attributed to an overdose of marijuana. Clearly, 
most prescription drugs are far more dangerous than marijuana."[25] 
In summary, overdose can easily happen, particularly, when a person orally ingests 
unstandardized product and is not tolerant to the herb, often resulting in a feeling that one 
will die…but none do.  
4.5 Strain specificity 
Important too, when considering dosage is the strain of cannabis in question. There are two 
subspecies of cannabis,  Indica and Sativa, and since they’re the same species they interbreed 
creating thousands of strains of cannabis each with its own unique pharmacology. It is this 
latter understanding that holds many of us to it as an extremely useful herbal medicine with 
a very broad efficacy.  
Firstly, correct strain selection is paramount for relief of chronic pain. In general the Indicas 
known as Kushs are widely used for pain relief, as are the Indicas as opposed to Sativas. The 
latter tend to be stimulatory and not as effective for pain. Indeed, Indica’s tend to have 
higher levels of Cannabidiol (CBD), a cannabinoid with demonstrated powerful anti-
inflammatory action (26). Our studies using HPLC to quantify cannabinoid concentrations 
in standardized capsules finds that a ratio roughly 1:10 CBD:THC, works well for pain relief 
in an oral preparation at doses of 20 to 100 mg (depending on tolerance) THC, every four to 
six hours (21,22).  
Often members at dispensaries will use the term “different strains for different pains”, to 
describe the effects of cannabis on their symptoms. Since high cannabidiol strains are rare, it 
has been difficult to study the effects of CBD on pain. Touted in the literature as being non-
psychoactive we observe markedly different effects with cannabis both smoked and in oral 
preparations when high CBD levels are found in a strain. CBD brings about sedation at 
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moderate concentrations and shows efficacy with seizure disorder, tremor and neuropathic 
pain. 
We have only discovered one re-producible strain in British Columbia that has a CBD count 
greater than 50 mg/gram dry, ground, flower weight and, indeed, this strain that has 
proven most useful in treating persons with chronic pain (patent app). The rarity of high 
CBD concentrations in B.C. cannabis and other parts of the world where cannabis is grown 
commercially is a result of selective breeding of high THC strains, over many years, such 
that cannabidiol has essentially been bred out of commercially available cannabis. 
Cannabidiol is useful for a number of reasons…importantly its anti-inflammatory action 
(26). This property is fully utilized in treating rheumatoid arthritis, irritable bowel 
syndrome, and bacterial injury, to name a few. Also important is the anti-psychotic effects of 
CBD, when administered in conjunction with THC. CBD appears to ‘buffer’ the action of 
THC at the receptor, allowing less chance of overdose, further permitting higher THC doses, 
necessary for chronic pain management. 
What this means is that CBD can be used to modulate and enhance the effects of THC, in 
pain management. We have previously discussed the differences in tolerance dependent on 
genealogy that many persons using cannabis therapeutically can easily overdose 
particularly on oral preparations. To avoid this we have provided members who are 
sensitive to cannabis, with high CBD capsules to take along with relatively high THC 
concentrations and thus prevent the fear and paranoia of overdose and ultimately allowing 
better pain relief. 
5. Cross reaction and allergy 
In all of our years studying cannabis effects on members of dispensaries or persons with an 
MMAR licenses, we have not observed cross-reaction with any other medications, including 
opiates (synergy observed, discussed below), anti-depressants, NSAIDS or steroids. The 
apparent neuroprotective, anti-oxidant and homeostatic properties of cannabis, no doubt, 
playing a role in the non-toxic events arising from combined drug interaction. What is 
observed occasionally is allergic response to cannabis. Although few in number, on rare 
occasions a member will present with hives, irritation of the nose, sneezing, itching, and 
redness of the eyes, symptoms of allergy. 
6. Opiate reduction 
Although we do not yet have hard data to present on the subject, repeated observation, plus 
a number of case studies demonstrate the phenomenon of significant reduction in opiate 
consumption when an individual begins using cannabis therapeutically, particularly by the 
oral route. In the case study on chronic pain (21) our subject, over the course of one year was 
able to set aside the following medications and is currently only using cannabis for pain 
management: Arthrotec, Flexeril, ketorolac, Tylenol 3 with codeine, Naprosyn, Percocet, 
gabapentin, Marinol, Lyrica, Supradol, oxycodin and Oxycontin for pain. Doxepin, 
Imovane, Cipralex, Trazadone, Elavil, Effexor XR for depression and HCTZ, Lipitor and 
ranitidine for a secondary hypercholesterolemia. Even the latter hypercholesterolemia has 
subsided since using cannabis. 
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Furthermore, other researchers have noted the same occurrence of opiate reduction or 
cessation with subsequent use of marijuana  (27). And, others have found synergy with 
opiates, to which we fully agree. Pain relief is better realized when cannabis is used 
concurrently with opiate medications than with either, alone (28). Dr. Donald Abrams’, 
Chief of Hematology-Oncology at San Francisco General Hospital research team found that 
plasma levels of opiates did not increase with concurrent use of cannabis, but surprisingly 
decreased in amounts, yet showed an increase in pain relief. This seemingly paradoxical 
effect was described as being pharmacodynamic rather than pharmacokinetic…the 
mechanism remains unexplained, but the finding is significant in that persons using opiates 
for pain relief could actually use less for equal or better pain relief if cannabis is included in 
the regimen (28). 
The observed reduction in opiate consumption, plus dispensary’s, repeatedly using 
cannabis to significantly reduce or eliminate other addictions suggests its role as a powerful 
harm reduction agent. Claims of the ability to de-rail crack cocaine and crystal meth 
addictions, plus reduce or eliminate heroin and methadone were frequently made by 
dispensary staff members. We believe this to be, once again, the ability of cannabis to lend 
homeostasis to the human CNS, allowing easier withdrawal and maintenance. 
7. Natural supplements 
As mentioned earlier in this document chronic pain often cycles with mood disorder. 
Anxiety and depression are close relatives to pain and although cannabis can help with the 
symptoms (provided the correct strain and dosage is selected), there are other natural 
supplements we have found useful for pain management. Taking the lead in popularity 
with our chronic pain population are free amino acids such as Tyrosine and DL-
Phenylalanine, indeed GABA is found to be useful in treating pain as well as anxiety. Other 
mood enhancing natural products commonly used in pain management are 
phosphatidylserine (PS) and phosphatidylcholine (PC), S-adenosyl methionine and, of 
course, B-complex. 
Frequently people using cannabis therapeutically, in time, want to eliminate synthetic 
pharmaceutical drugs from the repertoire entirely and therefore natural supplements fare 
well, and effectively, in their treatment.   
8. Terpenes 
It seems appropriate, at this time, to enter another realm of cannabis effects…the terpenes 
and aromatics contained in the flowers of the plant that are often misunderstood and not 
realized for medicinal importance. We’ve conducted experiments creating oral 
preparations for members that had equal amounts of THC. One, called the “bald” prep, 
had only THC, the other, termed the “hairy” prep, had an equal amount of THC as the 
“bald” prep, but also contained the sixty-odd other cannabinoids, plus the terpenes and 
other essential oils of marijuana. Members reported that the bald prep was 
boring…indeed it did help with pain, but not to the extent of the “hairy” prep, that 
provided euphoria and the full cannabis experience. Conclusions from this experiment, 
that the effects of cannabis are certainly not all about THC, as earlier literature tended to 
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suggest. We have often stated that there is a whole medicinal science called aroma 
therapy, that incidentally, has not had the use of cannabis essential oils, since they have 
been banned as long as the plant.  
We believe the terpenes, as a result of their chemistry, to be brain active molecules, acting 
more like anesthetics than receptor binding agonists, playing their role by interacting with 
nerve cell membranes and modulating subsequent neurotransmission. Failure to include 
terpenes in cannabis medicine will leave much out of cannabis effects and, furthermore, we 
do not agree with ozonating cannabis medicine, for sterilization purposes, since we fear the 
formation of free radicals and reactive acid species (29).  
And we do not believe euphoria should be left out of pain management, considering the 
therapy of laughter and smiles and the mood disorder that often cycles with chronic pain. 
Euphoria is medically recognized as a mental and emotional state defined as a profound 
sense of well-being. Technically, euphoria is an affect, but the term is often colloquially used 
to define emotion as an intense state of transcendent happiness combined with an 
overwhelming sense of contentment. The word derives from Greek, "power of enduring 
easily" (30). For those in chronic pain euphoria is welcomed as a break from “the banging 
drum” and although transient with cannabis it can lead to the preferred psychological state 
of a better quality of life. 
Euphoria is more common to smoked cannabis than oral, since the terpenes enter the blood 
stream via the lung and are not metabolized first by the liver, as with oral ingestion. 
9. Neuroimaging 
The inverse agonist MK-9470 makes it possible to produce in vivo images of the distribution 
of CB1 receptors in the human brain with positron emission tomography.[31] This work, 
graphically illustrates the abundance of the receptor and its locations.  
10. Conclusions 
Since discovery of the cannabinoid receptor by Raphael Merchoulam of the Hebrew 
University in Jerusalem in the early 1990’s there has been an absolute explosion in research 
on what is now called the endocannabinoid system. The system, that is ubiquitous in human 
physiology is so prolific that it has been said that the human body is “wired for cannabis”. 
Indeed the most common G-protein receptor site in the human brain binds THC. Given the 
magnitude of this system and its influence of human biochemistry, it is certainly not “of no 
medical value”, yet remains as a Schedule 1 drug in the United States.  
As stated a number of times in this Chapter we treat cannabis as a whole plant herbal 
medicine; we analyze it that way, standardize and quality control it, using the same QC 
parameters as set out by Health Canada for any other herbal medicine in the country. And 
we have studied its effects in humans for more than a decade.  
Having, in this time observed thousands of persons, most of them in chronic pain, using 
cannabis therapeutically, in retrospect, we are also impressed by the apparent lack of 
adverse effects and events seen. We know that panic and anxiety attacks following cannabis 
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use can often be avoided with correct strain selection and dosage. And all of these adverse 
effects are transient. 
After repeated observation, time and time again of desired effects in pain management with 
persons using cannabis we can only conclude it to be and extremely important and useful 
herbal medicine. Indeed, a witch’s brew of phenolics, flavanoids, vitamins, terpenes, 
cannabinoids, and many other compounds of medical and human interest, we have always 
maintained that with sufficient instrumentation and resources, we could complete the story 
on the efficacy and safety of cannabis, the whole plant herbal medicine.  
The fact that cannabis is illegal for most people often forces them to use synthetic painkillers 
that may prove harmful to liver, kidney and heart, with extended use. We have always 
promoted standardized, quality controlled, herbal cannabis medicine, and, as stated we do 
not highly purify or synthesize any of its components.  
We have not observed any toxic events with any human subjects…not once. Noted on rare 
occasions are allergic responses to cannabis smoke or oral ingestion that may prevent a 
person from further use, but never more adverse or toxic reactions to the plant. 
Having repeated this exhaustively, our team has concluded that marijuana is a safe and 
profoundly effective herbal medicine. So effective, in fact, that it has been banned across 
most of the world for almost 100 years. This is a tragedy, for those who suffer and could 
gain a new, extended quality of life, for those who do not know of the miracle of cannabis 
and for those who do.   
Research has always been difficult with no government grants or similar resources to 
support labor or required equipment cost, we have essentially funded the work ourselves, 
with the help of the dispensaries and their members. 
Apart from the occasional overdose, to which full recovery is made, we have only observed 
benefit in quality of life for those using cannabis therapeutically.  Sometimes these benefits 
are alarming with members setting aside walkers and dancing in waiting rooms, after using 
marijuana. We have worked with members with crushed, metal impregnated and 
amputated limbs, addicted to pharmaceutical and street drugs, suffering from bipolar, 
ADHD, anxiety and depression…all find apparent benefit. 
Seems astounding, maybe troubling, why this plant is illegal throughout most of the world, 
or maybe you’ve just figured it out too.  
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